Skip to content

A comparative study of seven and twenty one times levigation of Nishamalaki Churna with Nishamalaki Swarasa in type 2 diabetes

Pharmaceutical standardization of Sapta and Ekavinshati Nishamalaki Swarasa Bhavita Nishamalaki Churna and their comparative clinical efficacy in the management of Madhumeha (Type 2 Diabetes)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051694
Enrollment
40
Registered
2023-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

ITRA, Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Both the sexes having age between 30 to 60 years. 2. Patients having one among chief complaints of Madhumeha (Prabhuta- Avilamutrata, Pipasadhikya, Kshudhadhikya etc.) 3. Known patient of Type 2 diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS. 4. Patients having Fasting blood sugar level =126 mg/dl and =200 mg/dl and or PPBS level =200 mg/dl and =350 mg/dl30. 5. Patients on conventional (Allopathic) oral hypoglyemic agents with and without medications for management of diabetes unchanged over period of last 3 months.

Exclusion criteria

Exclusion criteria: 1. Age more than 60 and below 30 years 2. All patients of diabetes mellitus receiving insulin. 3. Patients having Fasting blood sugar level 200 mg/dl and or PPBS level 350 mg/dl. 4. Malignant and accelerated hypertensive. 5. Patients having chronic complications of Diabetes Mellitus i. Microvascular: Nephropathy. ii. Macrovascular: Coronary artery disease (Acute or recent MI), Acute Peripheral vascular disease & Acute Cerebro-vascular episode. And acute complications like Prameha Pidaka (non-healing wound), extensive Localized or systemic virulent infection, Diabetic ketoacidosis. iii. Other chronic debilitating diseases like STD etc. 6. HIV positive cases. 7. Secondary Diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Improvement in cardinal signs and symptoms after treatment and at the end of follow upTimepoint: Baseline, 12 weeks and 14 weeks

Secondary

MeasureTime frame
Improvement in biochemical parameters of bloodTimepoint: 90 days

Countries

India

Contacts

Public ContactPoorvi Mahabdi

ITRA, Jamnagar

patgiri@itra.edu.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026